Patient Hopes for Lupus Remission Following “Rollercoaster” Treatment

A woman described her “revolutionary” lupus treatment as a “rollercoaster” experience, expressing her hope for achieving remission from the condition. Katie Tinkler, a resident of Guildford, participated in a clinical trial focused on “repurposing” specific immune system cells from the body to target and eliminate the cells responsible for lupus. Ms. Tinkler is among three patients in the United Kingdom who have undergone CAR T-cell therapy for lupus’s most severe manifestation, a condition known to be life-threatening and capable of damaging organs such as the heart, lungs, brain, and kidneys. The mother of three and former fitness instructor informed BBC Radio Surrey that the therapy, administered in early November, was “very full on,” and she is currently recuperating at home. Ms. Tinkler’s primary symptoms included severe joint pain and fatigue; over the last 10 years, the disease had also impacted other organs, such as her kidneys and heart. She further stated, “It’s difficult to live with.” This NHS trial, spearheaded by University College London Hospitals NHS Foundation Trust and University College London, builds upon a previous trial conducted in Germany, where patients treated with the therapy over a year ago have since achieved remission. Ms. Tinkler, who has lived with lupus for 30 years, described the experience as a “hard treatment” but affirmed it was something her body genuinely required. She commented, “I don’t know how long it would have carried on under fire, as it has been in the last decade.” The therapeutic process involved three days of chemotherapy prior to the reintroduction of the cells into her body, an experience Ms. Tinkler characterized by saying, “It was a bit of a rollercoaster.” Claire Roddie, a consultant haematologist, explained that this “revolutionary” “one-and-done” treatment effectively “reboots” the immune system to deactivate the lupus process. She elaborated, “Instead of using conventional drugs, it’s taking the immune system and weaponising it against the underlying cause of the lupus.” She indicated that despite the early stage, there was optimism about replicating the positive outcomes observed in the German trials.